Efficacy and safety of lobaplatin combined with radiotherapy versus cisplatin plus radiotherapy for locally advanced cervical cancer

  Objective  To compare efficacy and safety of lobaplatin combined with radiotherapy versus cisplatin plus radiotherapy for locally advanced cervical cancer.

  Methods  A total of 100 cervical cancer patients in stage ⅡB by International Federation of Gynecology and Obstetrics (FIGO) were randomized into lobaplatin group and cisplatin group, with 50 patients in each group. Patients in the lobaplatin group were administered lobaplatin intravenously for 10 mg/m² once a week during radiotherapy, while patients in the cisplatin group were administered cisplatin intravenously for 30 mg/m² once a week during radiotherapy, both group was treated for five cycles. The effective rates, disease control rates, incidence rates of adverse events and overall survival rates were compared between the two groups.

  Results  Effective rates and disease control rates showed no statistically significant differences between the two groups(P>0.05). The incidence rates of nausea and vomiting were 40.0%(20/50) in the lobaplatin group, which was siginificantly lower than 76.0%(38/50) in the cisplatin group(P < 0.05); the incidence rates of other adverse events between the two groups showed no statistically significant differences(P>0.05).

  Conclusion  Lobaplatin is a more effective and safe agent for locally advanced cervical cancer treatment than cisplatin, which can provide a novel strategy for patients with locally advanced cervical cancer.